JP2001520012A - ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 - Google Patents
ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子Info
- Publication number
- JP2001520012A JP2001520012A JP2000516033A JP2000516033A JP2001520012A JP 2001520012 A JP2001520012 A JP 2001520012A JP 2000516033 A JP2000516033 A JP 2000516033A JP 2000516033 A JP2000516033 A JP 2000516033A JP 2001520012 A JP2001520012 A JP 2001520012A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gene
- nucleic acid
- cells
- gene product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 348
- 230000009385 viral infection Effects 0.000 title claims abstract description 55
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 54
- 230000005760 tumorsuppression Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 148
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 124
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 117
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 117
- 241000700605 Viruses Species 0.000 claims abstract description 106
- 230000001413 cellular effect Effects 0.000 claims abstract description 42
- 238000012216 screening Methods 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 267
- 102000004169 proteins and genes Human genes 0.000 claims description 74
- 150000001875 compounds Chemical class 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 40
- 230000004083 survival effect Effects 0.000 claims description 35
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 22
- 230000003211 malignant effect Effects 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 230000002018 overexpression Effects 0.000 claims description 14
- 108700008625 Reporter Genes Proteins 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 230000009467 reduction Effects 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 9
- 102100039436 DNA-binding protein inhibitor ID-3 Human genes 0.000 claims description 8
- 101710152064 DNA-binding protein inhibitor ID-3 Proteins 0.000 claims description 8
- 230000008030 elimination Effects 0.000 claims description 6
- 238000003379 elimination reaction Methods 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 6
- 102100028505 6-pyruvoyl tetrahydrobiopterin synthase Human genes 0.000 claims description 4
- 108010045523 6-pyruvoyltetrahydropterin synthase Proteins 0.000 claims description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 4
- 101150051240 DLX2 gene Proteins 0.000 claims description 4
- 101000795753 Homo sapiens mRNA decay activator protein ZFP36 Proteins 0.000 claims description 4
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 4
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 claims description 4
- 101700026522 SMAD7 Proteins 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 238000007306 functionalization reaction Methods 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 108091008743 testicular receptors 4 Proteins 0.000 claims description 3
- 108010070113 alpha-1,3-mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase I Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 101000798869 Escherichia phage Mu DDE-recombinase A Proteins 0.000 claims 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 21
- 238000004113 cell culture Methods 0.000 abstract description 20
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 5
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 abstract 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 89
- 208000015181 infectious disease Diseases 0.000 description 27
- 239000013598 vector Substances 0.000 description 27
- 230000005764 inhibitory process Effects 0.000 description 23
- 239000012634 fragment Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 239000003550 marker Substances 0.000 description 18
- 238000010561 standard procedure Methods 0.000 description 18
- 235000003642 hunger Nutrition 0.000 description 17
- 230000037351 starvation Effects 0.000 description 17
- 238000009396 hybridization Methods 0.000 description 16
- 241000702263 Reovirus sp. Species 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 108010017384 Blood Proteins Proteins 0.000 description 13
- 102000004506 Blood Proteins Human genes 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000029812 viral genome replication Effects 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 239000002502 liposome Substances 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108020005544 Antisense RNA Proteins 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003184 complementary RNA Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 230000001177 retroviral effect Effects 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 5
- 206010061309 Neoplasm progression Diseases 0.000 description 5
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 5
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 5
- 101150082045 U3 gene Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000002101 lytic effect Effects 0.000 description 5
- 229960004927 neomycin Drugs 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 230000005751 tumor progression Effects 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000005546 dideoxynucleotide Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000150452 Orthohantavirus Species 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000712891 Arenavirus Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 2
- 241000712471 Dhori virus Species 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 241000430519 Human rhinovirus sp. Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 208000032420 Latent Infection Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000702244 Orthoreovirus Species 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010030743 Tropomyosin Proteins 0.000 description 2
- 241000713325 Visna/maedi virus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 244000309743 astrovirus Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 208000037799 influenza C Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- -1 intravenously Chemical compound 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000020978 protein processing Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 102000004149 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000008104 Reoviridae Infections Diseases 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 102000005881 S100 Calcium Binding Protein A6 Human genes 0.000 description 1
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100335937 Schizosaccharomyces pombe (strain 972 / ATCC 24843) gas5 gene Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010065850 Tristetraprolin Proteins 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 101150077246 gas5 gene Proteins 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 102100031622 mRNA decay activator protein ZFP36 Human genes 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6202197P | 1997-10-10 | 1997-10-10 | |
| US60/062,021 | 1997-10-10 | ||
| PCT/US1998/021276 WO1999019481A2 (en) | 1997-10-10 | 1998-10-08 | Mammalian genes involved in viral infection and tumor suppression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009033300A Division JP2009100780A (ja) | 1997-10-10 | 2009-02-16 | ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001520012A true JP2001520012A (ja) | 2001-10-30 |
| JP2001520012A5 JP2001520012A5 (enExample) | 2006-01-05 |
Family
ID=22039706
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000516033A Withdrawn JP2001520012A (ja) | 1997-10-10 | 1998-10-08 | ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 |
| JP2009033300A Pending JP2009100780A (ja) | 1997-10-10 | 2009-02-16 | ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009033300A Pending JP2009100780A (ja) | 1997-10-10 | 2009-02-16 | ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1021536A2 (enExample) |
| JP (2) | JP2001520012A (enExample) |
| AU (1) | AU9604198A (enExample) |
| CA (2) | CA2305312C (enExample) |
| WO (1) | WO1999019481A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006507807A (ja) * | 2002-05-02 | 2006-03-09 | バンダービルト ユニバーシティー | ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001016323A2 (en) * | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| JP2002300900A (ja) * | 2001-04-05 | 2002-10-15 | National Institute Of Advanced Industrial & Technology | 腫瘍悪性化因子および腫瘍悪性化を抑制する化合物のスクリーニング方法 |
| WO2003002528A2 (en) * | 2001-06-29 | 2003-01-09 | Subsidiary No. 3 | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| EP2339009A1 (en) * | 2009-12-22 | 2011-06-29 | Sandoz Ag | Cold inducible promoter sequences |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU646799B2 (en) * | 1989-02-14 | 1994-03-10 | Amira, Inc. | Inhibiting transformation of cells having elevated purine metabolic enzyme activity |
| US5364783A (en) * | 1990-05-14 | 1994-11-15 | Massachusetts Institute Of Technology | Retrovirus promoter-trap vectors |
| US5350835A (en) * | 1991-11-05 | 1994-09-27 | Board Of Regents, University Of Texas | Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids |
| AU742243B2 (en) * | 1996-04-15 | 2001-12-20 | Vanderbilt University | Mammalian genes involved in viral infection and tumor suppression |
-
1998
- 1998-10-08 JP JP2000516033A patent/JP2001520012A/ja not_active Withdrawn
- 1998-10-08 CA CA2305312A patent/CA2305312C/en not_active Expired - Fee Related
- 1998-10-08 EP EP98949800A patent/EP1021536A2/en not_active Withdrawn
- 1998-10-08 CA CA2696653A patent/CA2696653A1/en not_active Abandoned
- 1998-10-08 AU AU96041/98A patent/AU9604198A/en not_active Abandoned
- 1998-10-08 WO PCT/US1998/021276 patent/WO1999019481A2/en not_active Ceased
-
2009
- 2009-02-16 JP JP2009033300A patent/JP2009100780A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006507807A (ja) * | 2002-05-02 | 2006-03-09 | バンダービルト ユニバーシティー | ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999019481A2 (en) | 1999-04-22 |
| AU9604198A (en) | 1999-05-03 |
| CA2305312A1 (en) | 1999-04-22 |
| CA2305312C (en) | 2010-03-23 |
| CA2696653A1 (en) | 1999-04-22 |
| WO1999019481A3 (en) | 1999-11-04 |
| EP1021536A2 (en) | 2000-07-26 |
| JP2009100780A (ja) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090092594A1 (en) | Mammalian genes involved in viral infection and tumor suppression | |
| US6653467B1 (en) | Medicament for treatment of Duchenne muscular dystrophy | |
| US6653466B2 (en) | Pharmaceutical composition for treatment of duchenne muscular dystrophy | |
| JP2002542805A (ja) | アデノ随伴ウイルス送達リボザイム組成物および使用方法 | |
| KR20210131310A (ko) | 아넬로좀 및 사용 방법 | |
| KR20210125990A (ko) | 단백질 대체 치료 양식을 운반하기 위한 아넬로좀 | |
| JPH07507213A (ja) | 消化器デフェンシン，そのｃＤＮＡ配列及び製造方法並びにその使用 | |
| JP2002505841A (ja) | 低酸素調節性遺伝子 | |
| US20150139999A1 (en) | Interferon antagonists, antibodies thereto, and associated methods of use | |
| JP2006507807A (ja) | ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 | |
| JP2002525081A (ja) | 低酸素により調節される遺伝子転写に特徴的な配列 | |
| JP2009100780A (ja) | ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 | |
| Wang et al. | Molecular characterization, expression of chicken TBK1 gene and its effect on IRF3 signaling pathway | |
| CN111041001B (zh) | 治疗kras突变型肿瘤的安全型柯萨奇病毒及其药物组合物 | |
| JP2000512129A (ja) | ブタレトロウィルス | |
| US20050112553A1 (en) | Mammalian genes involved in viral infection and tumor suppression | |
| JP2025538153A (ja) | 拡張型心筋症を引き起こす変異の修正のための筋特異的塩基エディター | |
| CN114277119A (zh) | 一种环状RNA circ-Arsb在制备防治骨质疏松产品中的应用 | |
| JP7764502B2 (ja) | 環状ＲＮＡ Ｃｉｒｃ－ＡＣＥ２翻訳によるポリペプチド及びその使用 | |
| CN115427573A (zh) | 用于治疗常染色体显性best1相关视网膜病的组合物 | |
| JP2003500336A (ja) | （自己）免疫疾患の治療におけるアポトーシス誘発剤の使用 | |
| AU2010201498A1 (en) | Mammalian Genes Involved in Viral Infection and Tumor Suppression | |
| CN109182488A (zh) | Hmgcs2作为慢性肾脏疾病肾脏纤维化治疗的新靶点 | |
| CN118685412A (zh) | Zbed6基因在调控动物骨骼肌萎缩中的应用 | |
| AU780210B2 (en) | Mammalian genes involved in viral infection and tumor suppression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051006 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080815 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081111 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081118 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081211 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081218 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090216 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090417 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090817 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091222 |